Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +13.25%
#3 Bitway Bitway +11.68%
#4 Glidr Glidr +9.69%
#5 Meteora Meteora +9.51%
#6 OPENLOOT OPENLOOT +8.29%
#7 Unit Pump Unit Pump +8.17%
#8 Pump.fun Pump.fun +8.17%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.80%
#10 eCash eCash +7.48%
Coin of the day
PulseChain PulseChain
設定
言語
日本
通貨
USD
テーマ
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
株式のランク #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
株価
$0.55
最終同期: 2025-02-11
時価総額
$28.90M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Marinus Pharmaceuticals, Inc. (MRNS)

カテゴリー

Healthcare
Marinus Pharmaceuticals, Inc.（MRNS）の収益
Sep 2024 時点の収益 TTM: $31.47M
Marinus Pharmaceuticals, Inc. の最新の財務報告によると、現在の収益 (TTM) は $31.47M です。2022 年には $25.48M の収益があり、これは 2021 年の $15.35M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Marinus Pharmaceuticals, Inc. の収益履歴（2012 ～ 2026）
各年末の収益
年 収益 変化
2026 (TTM) $31.47M 1.54%
2023 $30.99M 21.63%
2022 $25.48M 66.03%
2021 $15.35M 793.19%
2020 $1.72M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 $100.00K 0.00%
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 40,020.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 6,980.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 19,035.85%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 49,779.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH